| Jun 18 |
Marinus Pharmaceuticals reports data from refractory status epilepticus drug trial
|
| Jun 17 |
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study
|
| Jun 17 |
Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
|
| Jun 13 |
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
|
| Jun 6 |
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
|
| May 30 |
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
|
| May 27 |
Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data
|
| May 24 |
Candel Reports Upbeat Data From Lung Cancer Study
|
| May 24 |
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
|
| May 23 |
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
|
